OPHLY:OTCMKTS
Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
USDÂ 4,76
arrow_upward
+0,85%(+0,040) 1D
13 Okt., 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for OPHLY...
Open
USDÂ 4,78
High
USDÂ 4,78
Low
USDÂ 4,76
Mkt. cap
1,13Â bn
Avg. vol.
60,13Â k
Volume
82,82Â k
52-wk high
USDÂ 5,75
52-wk low
USDÂ 3,81
Beta
0,21
Shares outstanding
1,50Â mjd
No. of employees
4Â k
Open
USDÂ 4,78
High
USDÂ 4,78
Low
USDÂ 4,76
Mkt. cap
1,13Â bn
Avg. vol.
60,13Â k
Volume
82,82Â k
52-wk high
USDÂ 5,75
52-wk low
USDÂ 3,81
Beta
0,21
Shares outstanding
1,50Â mjd
No. of employees
4Â k
News stories
From web sources and news partners
GlobeNewswire
·
10 minute gelede
Owlting Group (NASDAQ: OWLS) and Decaf Open U.S. Dollar Accounts Beyond the United States on OwlPay Harbor
StockStory
·
37 minute gelede
1 S&P 500 Stock with Competitive Advantages and 2 We Brush Off
Investor's Business Daily
·
39 minute gelede
Dow Futures Rise; ASML Earnings Beat, CPI Inflation Due
Seeking Alpha
·
2 uur gelede
Dow Jones Industrial Average Monitor Update - A Look At 30 U.S. Large-Caps
Profile
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka.
Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948.
Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen.
Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb.
In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
About Ono Pharmaceutical ADR Representing 1/3rd Ord Shs
CEOGyo Sagara | Gyo Sagara
Employees4,21Â k
Founded1717
HeadquartersOsaka, Osaka-prefektuur, Japan
SectorPharmaceutical industry
Websiteono-pharma.com